Clinical Research Protocols

Clinical Research Protocols for Cancer Prevention

Compiled by Margaret Gross-King, RN, MS, OCN, and
Gail L. Shaw, MD, FACP
H. Lee Moffitt Cancer Center & Research Institute

This list of clinical research protocols relating to cancer prevention is compiled for your convenience.

Head and Neck Cancer

RTOG-9115 NCI-C91-0002 Chemoprevention Trial With Low-Dose 13-Cis-Retinoic Acid to Prevent Second Primary Tumors in Head and Neck Cancer Patients (Summary last modified 02/93).

Chairman Waun Ki Hong, University of Texas-MD Anderson Cancer Center, Houston, Tex. Lead organization: Radiation Therapy Oncology Group. Acceptable age range: 18 to 74.

EST-C-0590 Phase III Double-Blind Randomized Study of Low-Dose 13-CRA on Prevention of Second Primaries in Patients With Totally Resected Stage I/II Squamous Cell Carcinoma of the Head and Neck (Summary last modified 10/96).

Chairman Harlan A. Pinto, Stanford University Medical Center, Stanford, Calif. Lead organization: Eastern Cooperative Oncology Group. Acceptable age range: over 18.

MDA-DM-90096 Phase III Randomized Chemoprevention Study of Long-Term, Low-Dose Isotretinoin vs Vitamin A in Patients With Premalignant Lesions of the Oral Cavity (Summary last modified 12/96).

Chairman Scott M. Lippman, University of Texas-MD Anderson Cancer Center, Houston, Tex. Lead organization: University of Texas-MD Anderson Cancer Center. Acceptable age range: 18 and over.

Colorectal Cancer

CLB-9270 Phase III Randomized Chemoprevention Study of Aspirin in Patients With Curatively Treated Dukes Stage A/B1/B2/C Colorectal Cancer (Summary last modified 10/95).

Chairman Robert A. Sandler, University of North Carolina, Chapel Hill, NC. Lead organization: Cancer and Leukemia Group B. Acceptable age range: over 30 and under 75.

UARIZ-A88138 NCI-P92-0008 Phase III Randomized Study of the Effect of Wheat Bran Fiber on Adenomatous Polyp Recurrence and Rectal Mucosal Proliferation Rates in Patients With Resected Colorectal Adenoma (Summary last modified 06/96).


E-8292 Phase II Randomized, Double-Blind, Placebo-Controlled Study of High-Dose Folic Acid for the Prevention of Colorectal Cancer in Patients With Resected Adenomatous Polyps (Summary last modified 10/96).


SWOG-9041 Pilot Randomized, Placebo-Controlled Study of Calcium for Chemoprevention of Colorectal Adenomas and New Primary Carcinomas in Surgically Treated Patients (Summary last modified 02/95).

Chairman David Z. J. Chu, Beckman Research Institute of the City of Hope, Duarte, Calif. Lead organization: Southwest Oncology Group. Acceptable age range: any age.

DMS-CPHS-10293, NCI-P95-0063 Randomized, Double-Blind, Placebo-Controlled Study of Two Different Doses of Aspirin and Folic Acid (1 mg/d) for the Prevention of Recurrent Neoplastic Polyps of the Large Bowel in Patients With a History of Large Bowel Adenoma (Summary last modified 07/95).

Chairman John Baron, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Lead organization: Norris Cotton Cancer Center. Acceptable age range: 21 to 80.

Gynecologic Sites

NCCTG-906951 NCI-P91-0010 Phase III Randomized Study of Interferon Alpha Plus Laser Therapy Ablation vs Ablation Alone in Patients With CIN Grades I-III (Summary last modified 10/92).

Prostate Cancer

SWOG-9217 NCI-P93-0049 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Finasteride (Proscar) for the Chemoprevention of Prostate Cancer (Closed 12/6/96).

Chairman Ian M. Thompson, Brooke Army Medical Center, Fort Sam Houston, Tex. Lead organization: Southwest Oncology Group. Acceptable age range: 55 and over.

Lung Cancer

UCHSC-92382 Phase II Study of 13-CRA With or Without VIT-E for the Chemoprevention of Lung Cancer (Summary last modified 12/96).

Chairman Karen Kelly, University of Colorado Cancer Center, Denver, Colo. Lead organization: University of Colorado Cancer Center. Acceptable age range: over 18.

E-5593 Early Detection of Second Primary Lung Cancer by Sputum Cytology Immunostaining in Patients With Curatively Resected Stage I Non-Small Cell Lung Cancer (Summary last modified 10/95).

Chairman John C. Ruckdeschel, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. Lead organization: Eastern Cooperative Oncology Group. Acceptable age range: 18 and over.

NCI-92-C-0052C Pilot Study of Neuroendocrine Peptide Levels as Potential Predictors of Second Lung Cancer After Surgical Resection With Curative Intent in Stage I/II Non-Small Cell Lung Cancer (Summary last modified 03/96).


UCHSC-92385 Study to Evaluate the Reversion of Premalignant Markers Following Smoking Cessation in Patients at High Risk for Developing Lung Cancer (Summary last modified 06/96).

Chairman Allan Prochazka, University of Colorado Cancer Center, Denver, Colo. Lead organization: University of Colorado Cancer Center.Acceptable age range: over 30.

MDA-ID-91025 Phase III Double-Blind, Randomized Trial of 13-CRA vs Placebo to Prevent Second Primary Tumors in Patients With Totally Resected Stage I Non-Small Cell Lung Cancer (Summary last modified 07/96).

Chairman Scott M. Lippman, University of Texas-MD Anderson Cancer Center, Houston, Tex. Lead organization: University of Texas-MD Anderson Cancer Center. Acceptable age range: over 18.

Breast Cancer


NCI-94-C-0056J Pilot Chemoprevention Study of Tamoxifen and Fenretinide in Subjects at High Risk for Developing Invasive Breast Cancer (Summary last modified 10/96).


UARIZ-HSC-A93.116 NCI-P94-0060 Randomized Pilot Study to Evaluate the Role of Dietary Fat Reduction and an Increased Intake of Fruits and Vegetables for Prevention of Breast Cancer in Postmenopausal Women (Summary last modified 12/96).

Chairman Yei-Mei Peng, University of Arizona Cancer Center, Tucson, Ariz. Lead organization: University of Arizona Cancer Center. Acceptable age range: 50 to 65.

NSABP-P-1 Randomized, Placebo-Controlled Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer (Summary last modified 02/97).


Skin Cancer

NIAMS-91-AR-0161 Use of Isotretinoin for the Prevention of Skin Cancer in Patients With Xeroderma Pigmentosum or Nevoid Basal Cell Carcinoma Syndrome (Summary last modified 06/96).


Multiple Sites

EORTC-08871 Phase III Randomized Comparison of the Influence of Chemoprevention With Vitamin A and/or N-Acetylcysteine vs No Treatment on Development and Detection of Second Primary Cancers in Patients Curatively Treated for Laryngeal, Oral Cavity, and Non-Small Cell Lung Carcinoma (Summary last modified 12/96).

**PLCO-1** A 16-Year Randomized Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer - PLCO Trial (Summary last modified 12/96).


**Legend for Abbreviations:**

CLB = Cancer & Leukemia Group B  
DMS = Dartmouth-Hitchcock Medical Center  
E, EST = Eastern Cooperative Oncology Group  
EORTC = European Organization for Research on Treatment of Cancer  
MDA = MD Anderson Cancer Center  
NCCTG = North Central Cancer Treatment Group  
NCI = National Cancer Institute  
NIAMS = National Institute of Arthritis and Musculoskeletal and Skin Diseases  
NSABP = National Surgical Adjuvant Breast & Bowel Project  
PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Trial  
RTOG = Radiation Oncology Group  
SWOG = Southwest Oncology Group  
UARIZ = University of Arizona  
UCHSC = University of Colorado Health Sciences Center  
UKCCCR = United Kingdom Coordinating Committee on Cancer Research